CaaS Capital Management is a New York City-based global investment firm specializing in equity capital markets and liquidity provision, actively participating in both private and public markets. Their strategy focuses on Series B, Series C, Post-IPO Equity, and Private Equity rounds, aiming to assist businesses with capital-raising goals through meticulous risk controls and diversification.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (57% of deals). Average disclosed round size is $120.2M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$971.0M
Top Stage
Series C
Last 12 Mo
0
Team
SQ
Saif Qazi
Vice President
DH
Dr. Hua Yi
Managing Director
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Umoja Biopharma | Series C | $100M | Jan 2025 |
 HotSpot Therapeutics, Inc. | Series C | $100M | Nov 2021 |
 Artios Pharma Limited | Series C | $153M | Jul 2021 |
| Umoja Biopharma | Series B | $210M | Jun 2021 |
 StrideBio, Inc. | Series B | $81.5M | Mar 2021 |
 Amunix Pharmaceuticals, Inc. | Series B | $117M | Mar 2021 |
 Cyteir Therapeutics | Series C | $80M | Feb 2021 |
Top Co-Investors
Avidity Partners3 shared
Alexandria Venture Investments3 shared
Janus Henderson Investors2 shared
Venrock2 shared
Casdin Capital2 shared
Omega Funds2 shared
DCVC2 shared
Cormorant Asset Management2 shared
MPM Capital2 shared
Qiming Venture Partners USA2 shared
RTW Investments2 shared
SoftBank Vision Fund2 shared
LSP2 shared
Sofinnova Partners2 shared
RA Capital Management1 shared
Ally Bridge Group1 shared
Novo Holdings1 shared
Lightstone Ventures1 shared
Osage University Partners1 shared
Viking Global Investors1 shared
Last updated: 15 April 2026